SCHEMBL283919

SCHEMBL283919

NS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.75
PTGS2 P35354 7/20 0.69
PTGS1 P23219 6/20 0.69
CA2 P00918 10/20 0.67
CA1 P00915 8/20 0.67
CA9 Q16790 8/20 0.64
CA12 O43570 6/20 0.64
CA7 P43166 4/20 0.64
CA4 P22748 3/20 0.64
MAOA P21397 2/20 0.64
MAOB P27338 1/20 0.62
CA14 Q9ULX7 2/20 0.59
USP2 O75604 1/20 0.59
TSHR P16473 1/20 0.59
CA6 P23280 1/20 0.59
CA5A P35218 1/20 0.59
CA13 Q8N1Q1 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
AGO2 Q9UKV8 1/20 0.59
CA5B Q9Y2D0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31527705 1.00 SOS1 (0.75) SOS1PTGS2PTGS1CA2CA1
SCHEMBL8043459 0.97 SOS1 (0.72) SOS1PTGS2PTGS1CA2CA1
Hydrochloric Acid SCHEMBL29876112 0.97 SOS1 (0.72) SOS1PTGS2PTGS1CA2CA1
Iodide SCHEMBL28540305 0.97 SOS1 (0.72) SOS1PTGS2PTGS1CA2CA1
SCHEMBL1430142 0.93 CA2 (0.76) SOS1PTGS2PTGS1CA2CA1
SCHEMBL28385356 0.91 SOS1 (0.64) SOS1PTGS2PTGS1CA2CA1
Sulfanilamide SCHEMBL27994963 0.91 CA2 (0.77) SOS1PTGS2PTGS1CA2CA1
SCHEMBL27510169 0.87 SOS1 (1.00) SOS1PTGS2PTGS1CA2CA1
SCHEMBL202948 0.85 CA2 (0.81) CA2CA1CA9CA12CA7
Benzenesulfonamide SCHEMBL28328141 0.85 PTGS2 (0.65) SOS1PTGS2PTGS1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4660182-A1 NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2025-12-10 EP claimed
CN-120127231-A Composite solid electrolyte with carbon fluoride nitride as filler, and preparation method and application thereof 陕西科技大学 2025-06-10 CN claimed
CN-120091742-A Preparation method for effectively reducing defects of perovskite solar cell body 南开大学 2025-06-03 CN claimed
CN-119695270-A Polymer solid electrolyte based on single ion conductor and preparation method thereof 陕西科技大学 2025-03-25 CN claimed
CN-119528773-A N-alkylation method of sulfonamide compound 赣南医科大学 2025-02-28 CN claimed
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 CN claimed
CN-118994036-A Synthesis method of quinazolinone derivative 常州大学 2024-11-22 CN claimed
CN-118507836-B Electrolyte for secondary lithium metal battery 深圳欣界能源科技有限公司 2024-09-17 CN claimed
CN-118507836-A Electrolyte for secondary lithium metal battery 深圳欣界能源科技有限公司 2024-08-16 CN claimed
WO-2024159285-A1 NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2024-08-08 WO claimed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP claimed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US claimed
WO-2000076519-A1 SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO claimed
EP-1054886-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-11-29 EP claimed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO claimed
WO-1999040088-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-08-12 WO claimed
US-5686492-A NMR DIAGNOSTIC AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 1997-11-11 US claimed
EP-0799197-A1 DISUBSTITUTED P-FLUOROBENZOLSULFONAMIDES AND THEIR USE IN NMR DIAGNOSTICS SCHERING AKTIENGESELLSCHAFT (DE) 1997-10-08 EP claimed
WO-1996019447-A1 DISUBSTITUTED P-FLUOROBENZOLSULFONAMIDES AND THEIR USE IN NMR DIAGNOSTICS SCHERING AKTIENGESELLSCHAFT (DE) 1996-06-27 WO claimed
CN-1117291-A 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections UPJOHN CO (US) 1996-02-21 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 SOS1 1987/4885PTGS2 2444/4885PTGS1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.